AMLX - Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
2024-06-25 15:35:59 ET
Summary
- Amylyx Pharmaceuticals, Inc.'s relyvrio for ALS was voluntarily delisted in the U.S. and Canada, but has a chance to target this indication with the advancement of AMX0114; IND filing and trial initiation expected in 2024.
- Full data from the phase 2 HELIOS trial, using AMX0035 to treat patients with Wolfram syndrome, is expected Fall of 2024.
- Interim analysis from phase 3 ORION study, using AMX0035 to treat patients with progressive supranuclear palsy, expected mid-2025.
- The company could possibly acquire rights to phase 3 ready GLP-1 asset Avexitide; This depends upon meeting certain conditions under this agreement, including a favorable ruling from the Texas Bankruptcy Court.
Amylyx Pharmaceuticals, Inc. ( AMLX ) suffered a major setback this year when it voluntarily delisted its Amyotrophic lateral sclerosis [ALS] drug Relyvrio on April 4th of 2024. This was a huge blow to the company, definitely, but that doesn't mean that it doesn't have some opportunities to redeem itself in the coming years....
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition